Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-652 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days |
| Arm 2 | EXPERIMENTAL | ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days |
| Arm 3 | EXPERIMENTAL | ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days |
| Name | Type | Description |
|---|---|---|
| ABT-652 | DRUG | See arm description for details |
| Placebo | DRUG | See arm description for details |
Inclusion Criteria * Has current diagnosis of an excessive daytime sleepiness disorder, including narcolepsy, idiopathic hypersomnia, and obstructive sleep apnea * Age 18 to 60 years Exclusion Criteria * Has significant suicidal ideation * Has a history of substance abuse * Has a history of a certa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan, Astra-Zeneca |
| ResMed Inc. | RMD | 1 | N/A | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | - | Daridorexant, Non-orexin receptor antagonist medications for insomnia |
ABT-652 is an investigational small molecule being developed for the treatment of sleep disorders, specifically excessive daytime sleepiness. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
ABT-652 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT.
ABT-652 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 trial has been completed to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
ABT-652 has one completed Phase 1 clinical trial, NCT01124851, which studied the drug in 36 subjects with excessive daytime sleepiness in the United States. The trial was randomized, double-blind, and controlled.
ABT-652 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been authorized for marketing.